Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5297-5305

  Keepers, Tiffany R ^a   Gomez, Marcela ^a   Celeri, Chris ^a   Nichols, Wright W ^b   Krause, Kevin M ^a  

^a Cerexa Inc   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; COLISTIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SERUM ALBUMIN; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; CEFTAZIDIME;

ALBUMIN BLOOD LEVEL; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; WILD TYPE; ANTIBIOTIC RESISTANCE; DOSE RESPONSE; DRUG EFFECTS; ENTEROBACTERIACEAE; KINETICS; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAM RESISTANCE; CEFTAZIDIME; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROBACTERIACEAE; HUMANS; KINETICS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; SERUM ALBUMIN;

EID: 84906074469     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02894-14     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA.
2. Chen J, Shang X, Hu F, Lao X, Gao X, Zheng H, Yao W. 2013. β-Lactamase inhibitors: an update. Mini Rev. Med. Chem. 13:1846-1861. http://dx.doi.org/10.2174/13895575113139990074.
3. Drawz SM, Papp-Wallace KM, Bonomo RA. 2014. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob. Agents Chemother. 58:1835-1846. http://dx.doi.org/10.1128/AAC.00826-13.
4. Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. 2014. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob. Agents Chemother. 58:833-838. http://dx.doi.org/10.1128/AAC.01896-13.
5. Flamm RK, Stone GG, Sader HS, Jones RN, Nichols WW. 6 December 2013. Avibactam reverts the ceftazidime MIC 90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. J. Chemother. http://dx.doi.org/10.1179/1973947813Y.0000000145.
6. Sader HS, Castanheira M, Flamm RK, Farrell DJ, Jones RN. 2014. Antimicrobial activity of ceftazidime-avibactam tested against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob. Agents Chemother. 58:1684-1692. http://dx.doi.org/10.1128/AAC.02429-13.
7. Keepers TR, Gomez M, Nichols WW, Krause KM. 2012. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother., abstr E-1162.
8. Cuzon G, Naas T, Bogaerts P, Glupczynski Y, Nordmann P. 2012. Evaluation of a DNA microarray for the rapid detection of extended-spectrum β-lactamases (TEM, SHV and CTX-M), plasmid-mediated cephalosporinases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR and CMY-1-like/MOX) and carbapenemases (KPC, OXA-48, VIM, IMP and NDM). J. Antimicrob. Chemother. 67:1865-1869. http://dx.doi.org/10.1093/jac/dks156.
9. Check-Points Health BV. 2012. Check-MDR CT101 user manual. Check-Points Health BV, Wageningen, The Netherlands.
10. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. CLSI document M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Clinical and Laboratory Standards Institute. 1999. Methods for determining bactericidal activity of antimicrobial agents - approved guideline. CLSI document M26-A. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Deshpande L, Rhomberg PR, Fritsche TR, Sader HS, Jones RN. 2004. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagn. Microbiol. Infect. Dis. 50:73-75. http://dx.doi.org/10.1016/j.diagmicrobio.2004.04.011. (Pubitemid 39360265)
15. Sagent Pharmaceuticals. 2011. Ceftriaxone for injection, USP, package insert. Sagent Pharmaceuticals, Schaumburg, IL.
16. Poirel L, Naas T, Nordmann P. 2010. Diversity, epidemiology, and genetics of class D β-lactamases. Antimicrob. Agents Chemother. 54:24-38. http://dx.doi.org/10.1128/AAC.01512-08.
17. Kaitany KC, Klinger NV, June CM, Ramey ME, Bonomo RA, Powers RA, Leonard DA. 2013. Structures of the class D carbapenemases OXA-23 and OXA-146: mechanistic basis of activity against carbapenems, extended spectrum cephalosporins and aztreonam. Antimicrob. Agents Chemother. 57:4848-4855. http://dx.doi.org/10.1128/AAC.00762-13.
18. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PRS, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. 2013. Ceftazidime-avibactam: a novel cephalosporin/β- lactamase inhibitor combination. Drugs 73:159-177. http://dx.doi.org/10.1007/ s40265-013-0013-7.
19. Sagent Pharmaceuticals. 2012. Ceftazidime for injection, USP, package insert. Sagent Pharmaceuticals, Schaumburg, IL.
20. Sagent Pharmaceuticals. 2012. Piperacillin and tazobactam for injection, USP, package insert. Sagent Pharmaceuticals, Schaumburg, IL.
21. AstraZeneca Pharmaceuticals LP. 2013. Merrem® IV (meropenem for injection) package insert. AstraZeneca Pharmaceuticals LP, Wilmington, DE.
22. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE. 2012. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob. Agents Chemother. 56:4241-4249. http://dx.doi.org/10.1128/AAC.06426-11.
23. Dudhani RV, Turnidge JD, Coulthard K, Milne RW, Rayner CR, Li J, Nation RL. 2010. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob. Agents Chemother. 54:1117-1124. http://dx.doi.org/10.1128/AAC.01114-09.
24. Burgess DS, Hall RG, II. 2004. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis. 49:41-46. http://dx.doi.org/10.1016/j.diagmicrobio.2003.11.007. (Pubitemid 38595625)
25. Robin F, Krebs M, Delmas J, Gibold L, Mirande C, Bonnet R. 2011. In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli. J. Antimicrob. Chemother. 66:1052-1056. http://dx.doi.org/10. 1093/jac/dkr045.
26. Weiss WJ, Petersen PJ, Murphy TM, Tardio L, Yang Y, Bradford PA, Venkatesan AM, Abe T, Isoda T, Mihira A, Ushirogochi H, Takasake T, Projan S, O'Connell J, Mansour TS. 2004. In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors. Antimicrob. Agents Chemother. 48:4589-4596. http://dx.doi.org/10.1128/AAC.48.12.4589-4596.2004. (Pubitemid 39577658)
27. Corvec S, Furustrand Tafin U, Betrisey B, Borens O, Trampuz A. 2013. Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob. Agents Chemother. 57:1421-1427. http://dx.doi.org/10.1128/AAC.01718-12.
28. Albur M, Noel A, Bowker K, MacGowan A. 2012. Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 56:3441-3443. http://dx.doi.org/10.1128/AAC.05682-11.
29. Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, Nation RL, Li J. 2008. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J. Antimicrob. Chemother. 62:1311-1318. http://dx.doi.org/10.1093/jac/dkn425.
30. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. 2003. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 47:905-909. http://dx.doi.org/10.1128/AAC. 47.3.905-909.2003. (Pubitemid 36254214)
31. Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL. 2010. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 54:804-810. http://dx.doi.org/10.1128/AAC.01190- 09.
32. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, Nicolau DP. 2012. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 56:6137-6146. http://dx.doi.org/10. 1128/AAC.00851-12.
33. Housman ST, Crandon JL, Nichols WW, Nicolau DP. 2014. Efficacy of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model. Antimicrob. Agents Chemother. 58:1365-1371. http://dx.doi.org/10.1128/AAC.02161-13.